Nura Bio aims to treat neurodegeneration with a small molecule designed to block SARM1, a novel target involved in axon degeneration. Following positive Phase 1 results in healthy volunteers, the startup is now preparing for mid-stage clinical testing.
The post Neuro Startup Nura Bio Adds $68M to Spare Axons With Its Brain-Penetrating Drug appeared first on MedCity News.
